Comparison

BPC-157 vs. Thymosin Beta-4

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

BPC-157

Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.

Thymosin Beta-4

Thymosin Beta-4 forms a 1:1 complex with monomeric (G-)actin and is regarded as the principal actin-sequestering factor in many cell types, thereby influencing cytoskeletal dynamics and directional cell migration. Preclinical models additionally describe effects on endothelial cell migration and neovascularisation, as well as activation of survival signalling pathways (including ILK/Akt). The mechanistic evidence derives predominantly from cell-culture and animal models.

Evidence base

Highest evidence

Animal model

Human trial

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	BPC-157	Thymosin Beta-4
Australia	Banned	—
Switzerland	Unapproved	—
Germany	Unapproved	Unapproved
United States	Research only	Unapproved

Full entries

Frequently asked questions

What is the difference between BPC-157 and Thymosin Beta-4?: BPC-157 is classified as "Healing", while Thymosin Beta-4 is classified as "Healing". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, BPC-157 or Thymosin Beta-4?: The highest available evidence level is "Animal model" for BPC-157 and "Human trial" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of BPC-157 and Thymosin Beta-4 in Germany and the United States?: Germany: BPC-157 — Unapproved, Thymosin Beta-4 — Unapproved. United States: BPC-157 — Research only, Thymosin Beta-4 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

BPC-157

Thymosin Beta-4

Australia

Banned

—

Switzerland

Unapproved

—

Germany

Unapproved

United States

Research only

Unapproved

Frequently asked questions

What is the difference between BPC-157 and Thymosin Beta-4?

BPC-157 is classified as "Healing", while Thymosin Beta-4 is classified as "Healing". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, BPC-157 or Thymosin Beta-4?

The highest available evidence level is "Animal model" for BPC-157 and "Human trial" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of BPC-157 and Thymosin Beta-4 in Germany and the United States?

Germany: BPC-157 — Unapproved, Thymosin Beta-4 — Unapproved. United States: BPC-157 — Research only, Thymosin Beta-4 — Unapproved. These are factual summaries with source and review date on the individual pages.